- Home
- ALEC vs AMRN Comparison
ALEC vs AMRN Comparison
Compare ALEC & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALEC
- AMRN
- Stock Information
- Founded
- ALEC 2013
- AMRN 1989
- Country
- ALEC United States
- AMRN Ireland
- Employees
- ALEC N/A
- AMRN N/A
- Industry
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ALEC Health Care
- AMRN Health Care
- Exchange
- ALEC Nasdaq
- AMRN Nasdaq
- Market Cap
- ALEC 176.3M
- AMRN 189.2M
- IPO Year
- ALEC 2019
- AMRN 1993
- Fundamental
- Price
- ALEC $1.73
- AMRN $0.57
- Analyst Decision
- ALEC Buy
- AMRN Buy
- Analyst Count
- ALEC 6
- AMRN 1
- Target Price
- ALEC $11.75
- AMRN N/A
- AVG Volume (30 Days)
- ALEC 1.3M
- AMRN 1.7M
- Earning Date
- ALEC 02-25-2025
- AMRN 02-27-2025
- Dividend Yield
- ALEC N/A
- AMRN N/A
- EPS Growth
- ALEC N/A
- AMRN N/A
- EPS
- ALEC N/A
- AMRN N/A
- Revenue
- ALEC $61,508,000.00
- AMRN $241,021,000.00
- Revenue This Year
- ALEC N/A
- AMRN N/A
- Revenue Next Year
- ALEC $4.98
- AMRN N/A
- P/E Ratio
- ALEC N/A
- AMRN N/A
- Revenue Growth
- ALEC N/A
- AMRN N/A
- 52 Week Low
- ALEC $1.60
- AMRN $0.43
- 52 Week High
- ALEC $7.58
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- ALEC 34.59
- AMRN 62.67
- Support Level
- ALEC $1.60
- AMRN $0.43
- Resistance Level
- ALEC $1.82
- AMRN $0.49
- Average True Range (ATR)
- ALEC 0.14
- AMRN 0.04
- MACD
- ALEC 0.05
- AMRN 0.01
- Stochastic Oscillator
- ALEC 23.42
- AMRN 99.71
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.